Head-to-head · Cost-Efficiency Index
AgelessRx vs Hims & Hers
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
AgelessRx
Budget-first semaglutide shoppers who also want a longevity-medicine framing and occasional brand access.
Visit AgelessRxHims & Hers
People who want a familiar, app-driven consumer brand and only need semaglutide.
Visit Hims & HersThe verdict
AgelessRx takes it, leading the Cost-Efficiency Index 85 to 83. The lowest published semaglutide cost among our partners, with some brand-name access — but an undisclosed tirzepatide price leaves a hole in the value model. Hims & Hers still earns a B — People who want a familiar, app-driven consumer brand and only need semaglutide.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs AgelessRx.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | AgelessRx | Hims & Hers |
|---|---|---|
| Cost-Efficiency Index | 85/100 | 83/100 |
| Semaglutide / mo | $139/mo | $199/mo |
| Tirzepatide / mo | Not disclosed | Not disclosed |
| Semaglutide / yr (modeled) | $1,668 | $2,388 |
| Tirzepatide / yr (modeled) | — | — |
| Coverage | Not disclosed | All 50 states |
| Oral / sublingual | No | No |
| Brand-name access | Yes | Compounded only |
| Rank here | #17 | #22 |
AgelessRx
85/100Where the value is
- Low disclosed semaglutide price at $139/mo
- Offers some brand-name access
- Established longevity brand
The tradeoffs
- Tirzepatide price not disclosed — you can't fully model total cost
- States-served not disclosed
Hims & Hers
83/100Where the value is
- Nationwide
- Slick app experience
- Semaglutide priced up front for modeling
The tradeoffs
- Tirzepatide pricing not consistently disclosed
- Compounded supply has drawn industry-wide regulatory scrutiny
Regulatory note: the FDA issued a warning letter to Hims & Hers Health, Inc. dba Hims in September 2025. We still list and link to Hims & Hers; you should know the letter is on the public record before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.